Samsung BioLogics, Biogen Idec form South Korean JV to focus on biosimilars; Biogen ups stake in JV; Biogen to Sell its Stake in JV
Samsung BioLogics and Biogen Idec Inc. have formed a joint venture in South Korea that will develop, manufacture, and market biosimilars.
- Generic Drugs
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.